NCT00796055View on ClinicalTrials.gov

Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

June 30, 2010

Conditions
Cancer
Interventions
DRUG

MEDI-547

Administered at a dose and schedule as determined by the subject's enrollment cohort as a 60 minute IV infusion as part of a 21-day treatment cycle.

Trial Locations (2)

20892

Research Site, Bethesda

48201

Research Site, Detroit

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT00796055 - Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors | Biotech Hunter | Biotech Hunter